Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Cebranopadol is an investigational, first-in-class dual-NMR agonist in development for acute and chronic pain as well as opioid use disorderFive scientific presentations will feature preclinical and...
-
FDA grants Orphan Drug Designation (ODD) to Tris Pharma’s TRN-257 for the treatment of idiopathic hypersomnia, based on the plausible hypothesis that TRN-257 may be clinically superior to currently...
-
MONMOUTH JUNCTION, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company advancing transformative targeted CNS therapeutics, today announced...
-
Presentation by leading expert Andrew J. Cutler, MD, will examine the lifelong impact of ADHD, risks of leaving the condition untreated, and importance of individualized treatment Presentation will...
-
This Role Reflects the Company’s Commitment to Integrated Innovation Across Central Nervous System Disorders. Appointment Comes as Tris Prepares to Submit a New Drug Application (NDA) for...
-
– Encore data to be presented demonstrating that cebranopadol displays significant and sustained pain reduction with a distinguished safety profile following abdominoplasty and bunionectomy – –...
-
Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP receptors to work synergistically to modulate painIn both...
-
Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP receptors to work synergistically to modulate...
-
– Preferential MOP agonists such as oxycodone are often required for effective management of moderate to severe pain but come with significant risks of addiction and overdose – – With Dual NMR...